Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Japanese Patients With DSM-IV-TR Schizophrenia.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomaglumetad methionil (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors Denovo Biopharma

Most Recent Events

30 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
17 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
14 Oct 2010 Planned end date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com